TrialJournal of hematology & oncology2021
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002).
Yuankai Shi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
45 papers cite it
this paperpooled ittrialcites it